BioMarin Pharmaceutical | BMRN - Sales Revenues


BioMarin Pharmaceutical reported $990M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
Bayer EUR 10.87B 2.54B Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
Incyte USD 1.67B 400M Jun/2026
Insmed USD 425.49M 119.53M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Moderna USD 100M 289M Jun/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 12.14B 65M Mar/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
United Therapeutics USD 783.3M 1.8M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026